Palvella Therapeutics (PVLA) vs. Its Peers Head to Head Review

Palvella Therapeutics (NASDAQ:PVLA) is one of 1,068 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Palvella Therapeutics to related companies based on the strength of its valuation, profitability, analyst recommendations, institutional ownership, risk, earnings and dividends.

Insider & Institutional Ownership

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 6.4% of Palvella Therapeutics shares are held by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Palvella Therapeutics has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Palvella Therapeutics’ competitors have a beta of 3.67, indicating that their average share price is 267% more volatile than the S&P 500.

Profitability

This table compares Palvella Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-80.93%	-59.55%
Palvella Therapeutics Competitors	-3,409.82%	-236.05%	-32.89%

Earnings & Valuation

This table compares Palvella Therapeutics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Palvella Therapeutics	$42.81 million	-$24.54 million	-1.65
Palvella Therapeutics Competitors	$9.20 billion	$138.93 million	-7.45

Palvella Therapeutics’ competitors have higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent recommendations for Palvella Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	0	0	4	0	3.00
Palvella Therapeutics Competitors	8148	21804	49603	1309	2.55

Palvella Therapeutics currently has a consensus target price of $40.33, suggesting a potential upside of 101.77%. As a group, “Pharmaceutical preparations” companies have a potential upside of 243.46%. Given Palvella Therapeutics’ competitors higher probable upside, analysts plainly believe Palvella Therapeutics has less favorable growth aspects than its competitors.

Summary

Palvella Therapeutics competitors beat Palvella Therapeutics on 8 of the 13 factors compared.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.